NEW TECHNIQUE FOR QUANTIFYING ATRIAL FIBRILLATION

心房颤动是一种常见的疾病， 严重的发病率和死亡率。心房颤动的新疗法 纤颤正在迅速发展，然而， 明显缺乏工具来帮助临床医生确定哪种治疗 最适合特定的病人。 在第一阶段，我们研究了一组信号处理算法 旨在通过量化心房颤动的发生率， 电传播的时空结构。我们发现 算法不仅提供了一个可量化的测量的性质， 房颤，他们也让我们发现了一个新的现象， 发生在除颤电击失败期间。 在第二阶段，我们计划开发实时版本的算法 研究在第一阶段，并测试他们沿着与几个新的 心脏电生理实验室的算法。我们的临床 顾问们将调查算法在选择 为患者提供最佳治疗方案， 介入治疗，包括导管消融、心脏复律和 服用抗抑郁药。 拟定商业应用： 开发新的管理方法具有强烈的商业利益 心房颤动的患者有很多。假设 在第二阶段获得的临床结果建立在第一阶段的基础上， 预计在开发的技术的重大商业利益 这个戒酒会这我们将继续寻求最直接的途径， 商业化;将该技术许可给现有的 心脏电生理工作站

Atrial fibrillation is a common disorder and is associated with significant morbidity and mortality. New treatments for atrial fibrillation are being developed at a rapid pace, however, there is a clear lack of tools to assist the clinician in determining which treatment is best suited for a particular patient. During Phase I, we investigated a set of signal processing algorithms intended to assist in treatment of atrial fibrillation by quantifying the spatiotemporal structure of electrical propagation. We found that the algorithms not only provided a quantifiable measure of the nature of atrial fibrillation, they also allowed us to discover a new phenomena that occurs during failed defibrillation shocks. During Phase II we plan to develop a real-time version of the algorithms investigated during Phase I, and test them along with several new algorithms in the cardiac electrophysiology laboratory. Our Clinical Consultants will investigate the role of the algorithms in selecting optimal treatment regimes for patients and for guiding specific interventions including catheter ablation, cardioversion, and administration of antiarrhythmic medications. PROPOSED COMMERCIAL APPLICATION: There is intense commercial interest in development of new ways to manage the large number of patients with atrial fibrillation. Assuming that the clinical results obtained during Phase II build upon those of Phase I, we expect a significant commercial interest in the technology developed under this program. We will continue to pursue the most direct path to commercialization; licensing of this technology to existing vendors of cardiac electrophysiology workstations.